Vivtex

Company Overview

Vivtex Corporation focuses on enabling oral delivery of biologic and peptide therapeutics that conventionally require injections or infusions. The company’s proprietary platform, GI-ORIS™ (gastrointestinal organ robotic interface system), uses automated, physiologically relevant screening of the whole gut to inform formulation and absorption strategies for next-generation oral medicines.

Its approach targets oral delivery challenges across a range of disease areas, with initial applications in metabolic disease, inflammatory conditions and other indications where biologics have strong clinical rationale but limited oral options.

Headquarters and Global Presence

Vivtex is headquartered in Cambridge, Massachusetts, with additional operations that tie into European research partnerships and collaborations. The company was launched as a spin-out of research from the laboratories of Robert Langer at MIT and Giovanni Traverso at MIT/Harvard Medical School.

Founding and History

Vivtex was founded in 2018 to transform drug development by enabling oral biologic therapies. It began as a platform technology venture based on breakthrough gastrointestinal screening methods developed in academic labs, with the goal of creating a translational path for therapies traditionally restricted to parenteral administration.

Over time the company has engaged in collaborations with biotechnology firms to apply its GI-ORIS™ platform to a range of therapeutic challenges, demonstrating the versatility of its technology and positioning it as a partner for both established pharma and emerging biotech.

Therapy Areas and Focus

Vivtex does not focus on a single disease but rather on enabling oral administration of biologics and peptides across multiple therapeutic areas. Major application themes include:

• Metabolic disease (e.g., obesity, diabetes)
• Inflammatory diseases
• Targets where oral delivery could replace injectable biologics

Its R&D and partnership activities reflect flexibility to apply the platform where oral delivery has demonstrable clinical and patient benefit.

Technology Platforms and Modalities

Vivtex’s core technology is built around GI-ORIS™, a high-throughput, robotic simulation of the gastrointestinal tract that captures complex absorption dynamics outside the body. The system is designed to accelerate formulation screening, improve prediction of human oral bioavailability, and enable AI-integrated design of next-generation oral biologics and peptides.

The platform supports multiple modalities and has been used in research collaborations to evaluate peptide bioavailability, permeability and optimized oral formulations.

Key Personnel

• Jack Barbut, Chief Executive Officer
• Robert Langer, Co-Founder and Board Member
• Giovanni Traverso, Co-Founder and Board Member
• Thomas von Erlach, Senior Scientific Leadership
• Lena Fischer, Senior Vice President Finance & Operations
• Per Larsson, Vice President Computational Sciences
• James Wright, Senior Scientific Advisor

Strategic Partnerships

Vivtex has engaged in research and licensing collaborations with multiple biotechnology companies to apply its GI-ORIS™ platform to specific therapeutic programs. These include work with macrocycle discovery firms and peptide drug developers, as well as high-profile licensing arrangements with major pharmaceutical companies to explore oral biologics in metabolic disease and related areas.

A headline partnership in 2026 with Novo Nordisk is valued at up to $2.1 billion and aims to combine Vivtex’s oral delivery technology with Novo Nordisk’s metabolic disease portfolio to develop next-generation obesity and diabetes medicines that can be taken orally.

FAQ Section